Skip to main content
Clinical Trials/NCT02963883
NCT02963883
Completed
Not Applicable

Erythrocyte Transfusion Based on the Measurement of Central Venous Oxygen Saturation in Postoperative Cardiac Surgery: a Bicentric, Prospective Randomized Study

Centre Hospitalier Universitaire, Amiens2 sites in 1 country160 target enrollmentDecember 1, 2016
ConditionsCardiac Surgery

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Surgery
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
160
Locations
2
Primary Endpoint
Number of patients transfused
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

Postoperative erythrocytes transfusion is associated with morbidity and excess mortality, which should lead to ask the indication for RBC transfusions only on metabolic needs. Currently, the majority of studies used to put hemoglobin values indicating red cell transfusions. Two observational studies have confirmed that a transfusion strategy based on a metabolic index (ScvO2) individual was accompanied by a different transfusion strategy than using the hemoglobin threshold values. We propose to conduct the first randomized multicenter study to evaluate erythrocyte transfusion strategy in postoperative cardiac surgery using the ScvO2 each patient versus a threshold value usually recommended for all patients.

Detailed Description

Postoperative erythrocytes transfusion is associated with morbidity and excess mortality, which should lead to ask the indication for RBC transfusions only on metabolic needs. Currently, the majority of studies used to put hemoglobin values indicating red cell transfusions. Two observational studies have confirmed that a transfusion strategy based on a metabolic index (ScvO2) individual was accompanied by a different transfusion strategy than using the hemoglobin threshold values. We propose to conduct the first randomized multicenter study to evaluate erythrocyte transfusion strategy in postoperative cardiac surgery using the ScvO2 each patient versus a threshold value usually recommended for all patients.

Registry
clinicaltrials.gov
Start Date
December 1, 2016
End Date
May 28, 2020
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient ≥ 18 years
  • programmed cardiac surgery
  • Central venous catheter placed in territory SVC
  • Affiliation to a social security system
  • Hemoglobin \<9 g / dL (transfusion threshold retained by the recommendations the HAS in November 2014 for perioperative patients with cardiovascular antecedents)

Exclusion Criteria

  • Patient minor or under court protection
  • Pregnant or lactating women
  • severe acute hemorrhagic syndrome (defined by bleeding rate greater than 1.5 ml / kg / hour for 6 consecutive hours and / or surgical revision within the first 24 postoperative hours)
  • Installation of an external or internal circulatory support
  • emergency surgery (\<24 hours from admission)
  • Complex Aortic Surgery
  • Patient Refusal of transfusion (religious belief)
  • Patient under guardianship
  • Renal failure with dialysis treatment

Outcomes

Primary Outcomes

Number of patients transfused

Time Frame: 15 dys

Number of patients transfused at least one red blood cell concentrate in postoperative cardiac surgery for the ScvO2 group compared to the control group

Secondary Outcomes

  • Death(15 days)
  • stroke(15 days)
  • BNP Rate(15 days)
  • central venous O2 saturation (SVO2)(15 days)
  • SOFA score (sepsis organ failure assessment)(15 days)
  • myocardial infarction(15 days)
  • allergic complications including anaphylactic shock(15 days)
  • metabolic complications including febrile non-haemolytic reactions(15 days)
  • Rate of lactate(15 days)
  • Rate BNP(15 days)
  • acute pulmonary edema due to the overload(15 days)
  • lesional pulmonary edema or TRALI,(6 h)
  • immunological complications including allo-immunization(15 days)
  • lactate Rate(15 days)
  • acute renal failure,(15 days)
  • infectious complications(15 days)
  • Cost reduction of transfusion(15 days)

Study Sites (2)

Loading locations...

Similar Trials